Quoin Pharmaceuticals, Ltd.
QNRXHealthcare|Biotechnology|US
$3.65
-0.20 (-5.19%)
DCF Value
$2547.50
Tangible Book / Share
$5.63
Cash / Share
$2.00
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06953466 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | Netherton Syndrome | P2P3 | Recruiting | 8 | Open-label | QRX003, 4% Lotion |
| NCT05521438 Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome | Netherton Syndrome | P2P3 | Active | 30 | RCT, Double-blind | QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle, QRX003-4% Lotion BID |
| NCT07538583 Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | Netherton Syndrome | P2P3 | Recruiting | 16 | Open-label | QRX003 |
| NCT05789056 Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome | Netherton Syndrome | P2P3 | Recruiting | 20 | Open-label | QRX003, 4% Lotion |